NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines
AD Zelenetz, LI Gordon, JE Chang, B Christian… - Journal of the National …, 2021 - jnccn.org
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …
CAR T-cell therapy in the older person: indications and risks
G Shouse, AV Danilov, A Artz - Current Oncology Reports, 2022 - Springer
Abstract Purpose of Review Validated metrics to optimize older adult patient selection for
Chimeric Antigen Receptor T-cell therapy (CART) are lacking; however, some preliminary …
Chimeric Antigen Receptor T-cell therapy (CART) are lacking; however, some preliminary …
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Y Song, K Zhou, D Zou, J Zhou, J Hu… - Blood, The Journal …, 2022 - ashpublications.org
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …
Bi-and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
I Abou Dalle, R Dulery, N Moukalled, L Ricard… - Blood Cancer …, 2024 - nature.com
Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase
1/2 study in patients with various B-cell malignancies. In the subgroup of patients with …
1/2 study in patients with various B-cell malignancies. In the subgroup of patients with …
Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers
ML Wang, JC Barrientos, RR Furman, M Mei… - NEJM …, 2022 - evidence.nejm.org
Background Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein
present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate …
present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate …
Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world …
PURPOSE Commonly used first-line (1L) treatments for mantle cell lymphoma include high-
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
A Noy, S de Vos, M Coleman, P Martin… - Blood …, 2020 - ashpublications.org
Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on
B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and …
B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and …
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare
phenomenon with dismal prognosis, where no standard therapy exists. Since the covalent …
phenomenon with dismal prognosis, where no standard therapy exists. Since the covalent …
[HTML][HTML] Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 …
M Dreyling, A Goy, G Hess, BS Kahl… - …, 2022 - journals.lww.com
The data-sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is
available at www. janssen. com/clinical-trials/transparency. Requests for access to data from …
available at www. janssen. com/clinical-trials/transparency. Requests for access to data from …